OncoMatch/Clinical Trials/NCT06316960
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
Is NCT06316960 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for aml, childhood.
Treatment: Avapritinib · Azacitidine · Decitabine · Idarubicin Hydrochloride · Cytarabine · Granulocyte Colony-Stimulating Factor — The purpose of this study is to evaluate the efficacy and safety of avapritinib in relapsed or refractory pediatric core binding factor acute myeloid leukemia with KIT mutation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: KIT mutation
KIT mutation
Required: RUNX1 fusion with RUNX1T1
Presence of t(8;21)/RUNX1::RUNX1T1
Required: CBFB fusion with MYH11
inv(16)/t(16;16)/CBFβ::MYH11
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: KIT inhibitor (avapritinib)
Have received prior treatment with avapritinib
Lab requirements
Kidney function
creatinine clearance ≥50ml/min
Liver function
tbil ≤2×uln, alt/ast ≤3×uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06316960 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior KIT inhibitor disqualifies patients from enrollment.
Does this trial require KIT?
Yes, KIT mutation is a required biomarker for enrollment.
Does this trial require RUNX1?
Yes, RUNX1 fusion with RUNX1T1 is a required biomarker for enrollment.
Does this trial require CBFB?
Yes, CBFB fusion with MYH11 is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 18 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages